Governance Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
4.780 ^USD	-1.65%		+0.84%	-0.21%

06-30	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Value-Defensive Index	CI
06-30	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to Russell 2000 Defensive Index	CI

Executive Committee: Vanda Pharmaceuticals Inc.

Manager

Positions heldSince

Mihael Polymeropoulos

65 year

Chief Executive Officer	30/04/2003
Founder	31/10/2002
President	30/04/2003

Tim Williams

49 year

General Counsel	12/08/2018
Corporate Secretary	12/08/2018

Kim Wijkstrom

59 year

Sales & Marketing

20/08/2019

Scott Howell

Human Resources Officer

31/07/2019

Kevin Moran

41 year

Director of Finance/CFO	14/03/2020
Investor Relations Contact	30/11/2012
Treasurer	14/03/2020

Composition of the Board of Directors: Vanda Pharmaceuticals Inc.

Director

CommitteesSince

Mihael Polymeropoulos

65 year

Chairman

31/05/2021

Anne Ward

53 year

Audit Committee	05/11/2020
Compensation Committee Chair
Governance Committee Chair	05/11/2020
Nominating Committee Chair	05/11/2020

Tage Honoré

74 year

Compensation Committee	14/03/2023
Governance Committee	14/03/2023
Nominating Committee	14/03/2023

Phaedra Chrousos

45 year

Audit Committee	23/04/2019
Governance Committee Chair
Nominating Committee Chair

Stephen Mitchell

73 year

Governance Committee	13/02/2020
Nominating Committee	13/02/2020

Richard Dugan

83 year

Compensation Committee	30/11/2005
Audit Committee Chair	30/11/2005

Latest Appointments: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. Appoints Dr. Tage Honoré to its Board of Directors	17/03/23	CI
H. Thomas Watkins Not Stands for Reelection of Vanda Pharmaceuticals Inc	25/04/22	CI
Vanda Pharmaceuticals Inc. Announces Resignation of Aranthan “Aj” Jones II as the Corporate Affairs and Communications Officer	08/10/21	CI
Vanda Pharmaceuticals Inc. Announces Resignation of Mihael H. Polymeropoulos as Director	22/04/20	CI
Vanda Pharmaceuticals Inc. Announces Resignation of Gian Piero Reverberi as Senior Vice President and Chief Commercial Officer, Effective as of March 16, 2020	03/03/20	CI
Vanda Pharmaceuticals Inc. Announces Executive Changes, Effective March 15, 2020	20/02/20	CI
Vanda Pharmaceuticals Inc. Announces Board Changes	19/02/20	CI

More news

Former Officers and Directors: Vanda Pharmaceuticals Inc.

Insider

Positions held

SinceUntil

H. Watkins

Director/Board Member	11/09/2006	31/10/2011
Chairman	30/03/2014	-
Independent Dir/Board Member	11/09/2006	15/06/2022

Aranthan Jones

Public Communications Contact	20/08/2019	25/10/2021
General Counsel	20/08/2019	25/10/2021

Gian Reverberi

Corporate Officer/Principal

07/09/2015

15/03/2020

James Kelly

Comptroller/Controller/Auditor	-	12/08/2018
Director of Finance/CFO	14/12/2010	14/03/2020
Investor Relations Contact	12/12/2010	14/03/2020
Corporate Secretary	14/12/2010	12/08/2018
Treasurer	14/12/2010	14/03/2020

Michael Cola

Director/Board Member	17/06/2012	13/02/2020
Independent Dir/Board Member	17/06/2012	13/02/2020

Vin Milano Milano

Director/Board Member	20/04/2010	12/06/2019
Independent Dir/Board Member	14/04/2010	12/06/2019

Ken Bate

Director/Board Member	16/12/2015	12/06/2018
Independent Dir/Board Member	16/12/2015	12/06/2018

Richard L. Gulino

General Counsel	13/09/2015	01/05/2018
Corporate Secretary	13/09/2015	01/05/2018

Howard H. Pien

Director/Board Member	04/06/2007	31/12/2009
Chairman	31/12/2009	31/12/2015
Independent Dir/Board Member	04/06/2007	31/12/2009

Thomas Gibbs

Corporate Officer/Principal	19/04/2015	16/12/2015
Corporate Officer/Principal	28/02/2015	30/11/2015

Steven Galson

Director/Board Member	01/07/2010	17/06/2015
Independent Dir/Board Member	30/06/2010	17/06/2015

Philip Herman

Sales & Marketing

31/12/2012

28/02/2015

Robert Repella

Corporate Officer/Principal

25/10/2011

Joseph A. Sliman

Chief Tech/Sci/R&D Officer

31/08/2012

31/12/2013

Argeris Karabelas

Director/Board Member	14/11/2011	17/01/2012
Chairman	17/11/2009	14/11/2011
Founder	31/12/2001	14/11/2011
Independent Dir/Board Member	15/11/2011	17/01/2012

Stephanie R. Irish

Comptroller/Controller/Auditor	05/08/2010	05/08/2010
Director of Finance/CFO	05/08/2010	05/08/2010
Corporate Secretary	05/08/2010	05/08/2010
Treasurer	05/08/2010	05/08/2010

Brian Halak

Director/Board Member

31/12/2003

20/04/2010

Chip Clark

Founder	31/12/2001	25/03/2010
Corporate Secretary	31/12/2002	25/03/2010

David Ramsay

Director/Board Member

31/12/2003

06/01/2010

Frederick H. Graff

Sales & Marketing

31/12/2007

31/12/2009

Steven Shallcross

Director of Finance/CFO	31/10/2005	08/01/2009
Treasurer	31/10/2005	08/01/2009

Paolo Baroldi

Chief Tech/Sci/R&D Officer	30/06/2006	08/01/2009
Chief Tech/Sci/R&D Officer	16/04/2013	21/03/2017

Todd Horich

Sales & Marketing

31/12/2005

31/12/2008

Albert W. Gianchetti

Corporate Officer/Principal

24/10/2007

30/11/2008

Jan Smilek

Director of Finance/CFO

31/12/2005

31/01/2008

John Joseph Feeney

Chief Tech/Sci/R&D Officer

08/01/2009

Thomas Lyle Copmann

General Counsel

31/03/2005

23/10/2007

James Tananbaum

Director/Board Member

31/12/2003

04/06/2007

Wayne T. Hockmeyer

Director/Board Member

31/12/2003

11/09/2006

Heng Tong Choo

Director/Board Member

Ankit Mahadevia

Corporate Officer/Principal

Curt Wolfgang

General Counsel

Cristina Murphy

Investor Relations Contact	25/10/2011	-
Public Communications Contact	04/07/2010	-

Mark Leschly

Director/Board Member

Ashish Khanna

Corporate Officer/Principal

Christian Lavedan

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	10
Female	2

Of which Executive Committee

Male	5
Female	0

Of which Directors

Male	4
Female	2

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

CCC

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

368

Sector

Biotechnology & Medical Research

Calendar

07-23 - Q2 2025 Earnings Release (Projected)

More about the company